Section Arrow
Quote
KNSA.NASDAQ
- Kiniksa Pharmaceuticals International, plc
Quotes are at least 15-min delayed:2026/07/19 13:27 EDT
Regular Hours
Last
 63.95
+2.84 (+4.65%)
Day High 
64.63 
Prev. Close
61.11 
1-M High
67.53 
Volume 
712.52K 
Bid
59.2
Ask
64.66
Day Low
60.065 
Open
60.09 
1-M Low
52.68 
Market Cap 
4.70B 
Currency 美元 
P/E 67.15 
%Yield -- 
10-SMA 63.39 
20-SMA 61.21 
50-SMA 56.3 
52-W High 67.53 
52-W Low 26.27 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.91/1.32
Enterprise Value
4.71B
Balance Sheet
Book Value Per Share
7.87
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
677.56M
Operating Revenue Per Share
3.23
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health32.84-0.84-2.49%-- 
VTRSViatris17.29-0.04-0.23%-- 
HLNHaleon plc10.1-0.01-0.10%20.28PE
ZTSZOETIS76.56-0.35-0.46%12.61PE
TAKTakeda Pharmaceutical Company Limited17.15+0.42+2.51%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.